Geovax Stock Story

GOVX -  USA Stock  

USD 4.37  0.27  5.82%

While some of us are excited about healthcare space, it makes sense to break down Geovax Labs in greater detail to make a better assessment of its actual value. We will analyze why Geovax Labs investors may still consider a stake in the business. Is Geovax Labs valuation justified? Here I will cover 2021 perspective on the current valuation of the firm to give you a better outlook on taking a possible position in this stock.
Published over three months ago
View all stories for Geovax Labs | View All Stories
Is Geovax Labs (NASDAQ:GOVX) ready for a correction?
Geovax Labs currently holds 198.06 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Geovax Labs is UNDERVALUED at 6.51 per share with modest projections ahead.
We determine the current worth of Geovax Labs using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Geovax Labs based exclusively on its fundamental and basic technical indicators. By analyzing Geovax Labs's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Geovax Labs's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Geovax Labs. We calculate exposure to Geovax Labs's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Geovax Labs's related companies.

Geovax Labs Investment Alerts

Geovax investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Geovax Labs performance across your portfolios.Please check all investment alerts for Geovax

Geovax Labs Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Geovax value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Geovax Labs competition to find correlations between indicators driving the intrinsic value of Geovax.

How Geovax utilizes its cash?

To perform a cash flow analysis of Geovax Labs, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Geovax Labs is receiving and how much cash it distributes out in a given period. The Geovax Labs cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Geovax Labs Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Geovax Labs reported Net Cash Flow from Operations of (2.75 Million) in 2020

Purchase by Dean Kollintzas of 11987 shares of GEOVAX LABS

Legal trades by Geovax Labs insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
GEOVAX insider trading alert for perchase of common stock purchase warrant by Dean Kollintzas, the corporate stakeholder, on 29th of September 2020. This event was filed by Geovax Labs Inc with SEC on 2020-09-29. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another angle On Geovax Labs

The entity reported the previous year's revenue of 1.82 M. Net Loss for the year was (2.96 M) with loss before overhead, payroll, taxes, and interest of (620.8 K).

Margins Breakdown

Geovax profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Geovax Labs itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Geovax Labs profit margins.
EBITDA Margin(1.65)
Gross Margin0.89
Profit Margin(1.75)


Geovax Labs Average Assets is fairly stable at the moment. Moreover, Geovax Labs Earnings Before Interest Taxes and Depreciation Amortization USD is fairly stable at the moment.

Geovax Labs implied volatility may change after the rise

Geovax Labs current jensen alpha rises over 0.82. Geovax Labs is displaying above-average volatility over the selected time horizon. Investors should scrutinize Geovax Labs independently to ensure intended market timing strategies are aligned with expectations about Geovax Labs volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Geovax Labs' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Geovax Labs' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Geovax Labs

While many other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Geovax Labs may offer a potential longer-term growth to investors. All things considered, as of the 13th of April 2021, our primary 30 days buy-or-sell advice on the company is Hold. We believe Geovax Labs is undervalued with very small chance of distress for the next two years.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Geovax Labs. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com